{"id":349154,"date":"2026-11-17T09:33:42","date_gmt":"2026-11-17T04:03:42","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=349154"},"modified":"2026-11-20T16:49:56","modified_gmt":"2026-11-20T11:19:56","slug":"gland-pharma-share-price-target-2027-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/","title":{"rendered":"Gland Pharma Share Price Target 2027: Rs 3,812 Base"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Gland Pharma share price Rs 3,385.90 (17 November 2026). Base target Rs 3,812, bull Rs 4,611, downside risk Rs 2,646. PE 44.16. 52W range Rs 1,573.60 to Rs 3,429.00.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The <strong>Gland Pharma share price target<\/strong> for 2027 is <strong>Rs 3,812<\/strong>, about <strong>12.6%<\/strong> above the current price of Rs 3,385.90. The <strong>bull case<\/strong> is <strong>Rs 4,611<\/strong>, and the <strong>downside risk level<\/strong>, which is not a target, is <strong>Rs 2,646<\/strong>. The base case assumes earnings per share grow 15.2% a year, the pace seen from FY24 to FY26, with the stock holding its PE of 44.16. These are model-based estimates built from reported financials, not guaranteed outcomes.<\/p>\n<\/p><\/div>\n<p>Investors weighing a <strong>Gland Pharma target price<\/strong> for 2027 should start with where the stock sits today. At Rs 3,385.90 on 17 November 2026, it is 1.3% below its 52-week high of Rs 3,429.00 and 115.2% above its 52-week low of Rs 1,573.60. That range spans 118% from low to high, so the entry point matters as much as the <strong>Gland Pharma price forecast<\/strong> itself.<\/p>\n<p>This article builds the <strong>Gland Pharma share price target<\/strong> from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the <strong>bull case<\/strong> and the <strong>downside risk level<\/strong> were reached and test them against your own view.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&amp;utm_medium=gland-pharma-share-price-target-2027\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Gland_Pharma_Stock_Analysis_Company_Overview_and_Key_Stats\" title=\"Gland Pharma Stock Analysis: Company Overview and Key Stats\">Gland Pharma Stock Analysis: Company Overview and Key Stats<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Why_Is_Gland_Pharma_Share_Price_Target_Set_at_Rs_3812_for_2027\" title=\"Why Is Gland Pharma Share Price Target Set at Rs 3,812 for 2027?\">Why Is Gland Pharma Share Price Target Set at Rs 3,812 for 2027?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Earnings_Growth_Behind_the_Gland_Pharma_Target_Price_Five_Years_of_Results\" title=\"Earnings Growth Behind the Gland Pharma Target Price: Five Years of Results\">Earnings Growth Behind the Gland Pharma Target Price: Five Years of Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Margins_and_the_Latest_Quarter\" title=\"Margins and the Latest Quarter\">Margins and the Latest Quarter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Balance_Sheet_and_Cash_Flow\" title=\"Balance Sheet and Cash Flow\">Balance Sheet and Cash Flow<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Valuation_Check_for_the_Gland_Pharma_Stock_Target_PE_Price_to_Book_and_ROE\" title=\"Valuation Check for the Gland Pharma Stock Target: PE, Price to Book and ROE\">Valuation Check for the Gland Pharma Stock Target: PE, Price to Book and ROE<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Shareholding_Pattern_and_Institutional_Holding\" title=\"Shareholding Pattern and Institutional Holding\">Shareholding Pattern and Institutional Holding<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Gland_Pharma_Share_Price_Targets_for_the_Short_Term_and_12_Months\" title=\"Gland Pharma Share Price Targets for the Short Term and 12 Months\">Gland Pharma Share Price Targets for the Short Term and 12 Months<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Short_Term_Gland_Pharma_Stock_Target_Levels_Technical_Setup\" title=\"Short Term Gland Pharma Stock Target Levels: Technical Setup\">Short Term Gland Pharma Stock Target Levels: Technical Setup<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#12_Month_Gland_Pharma_Target_Price_for_2027\" title=\"12 Month Gland Pharma Target Price for 2027\">12 Month Gland Pharma Target Price for 2027<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#How_EPS_Growth_and_PE_Multiple_Change_the_Gland_Pharma_Target_Price\" title=\"How EPS Growth and PE Multiple Change the Gland Pharma Target Price\">How EPS Growth and PE Multiple Change the Gland Pharma Target Price<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Bull_Case_and_Downside_Risk_for_Gland_Pharma_Stock_Target_in_2027\" title=\"Bull Case and Downside Risk for Gland Pharma Stock Target in 2027\">Bull Case and Downside Risk for Gland Pharma Stock Target in 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Bull_Case_Rs_4611\" title=\"Bull Case Rs 4,611\">Bull Case Rs 4,611<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Downside_Risk_Level_Rs_2646\" title=\"Downside Risk Level Rs 2,646\">Downside Risk Level Rs 2,646<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Key_Risks_to_the_Gland_Pharma_Target_Price_for_2027\" title=\"Key Risks to the Gland Pharma Target Price for 2027\">Key Risks to the Gland Pharma Target Price for 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Growth_Slowdown_Risk_for_the_Gland_Pharma_Price_Target\" title=\"Growth Slowdown Risk for the Gland Pharma Price Target\">Growth Slowdown Risk for the Gland Pharma Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Liquidity_and_Size_Risk\" title=\"Liquidity and Size Risk\">Liquidity and Size Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Valuation_and_Margin_Risk\" title=\"Valuation and Margin Risk\">Valuation and Margin Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Market_and_Technical_Risk\" title=\"Market and Technical Risk\">Market and Technical Risk<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#How_to_Invest_in_Gland_Pharma\" title=\"How to Invest in Gland Pharma\">How to Invest in Gland Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#FAQs_on_Gland_Pharma_Share_Price_Target_2027\" title=\"FAQs on Gland Pharma Share Price Target 2027\">FAQs on Gland Pharma Share Price Target 2027<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#What_is_the_Gland_Pharma_share_price_target_for_2027\" title=\"What is the Gland Pharma share price target for 2027?\">What is the Gland Pharma share price target for 2027?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#What_is_the_Gland_Pharma_share_price_today\" title=\"What is the Gland Pharma share price today?\">What is the Gland Pharma share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Is_Gland_Pharma_a_buy_or_sell_at_the_current_price\" title=\"Is Gland Pharma a buy or sell at the current price?\">Is Gland Pharma a buy or sell at the current price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#What_are_the_bull_case_target_and_downside_risk_level_for_Gland_Pharma_shares\" title=\"What are the bull case target and downside risk level for Gland Pharma shares?\">What are the bull case target and downside risk level for Gland Pharma shares?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#What_are_the_main_risks_to_the_Gland_Pharma_price_target\" title=\"What are the main risks to the Gland Pharma price target?\">What are the main risks to the Gland Pharma price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#What_is_the_PE_ratio_of_Gland_Pharma_and_how_does_it_compare_with_the_industry\" title=\"What is the PE ratio of Gland Pharma and how does it compare with the industry?\">What is the PE ratio of Gland Pharma and how does it compare with the industry?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#Who_owns_Gland_Pharma_and_what_is_the_promoter_holding\" title=\"Who owns Gland Pharma, and what is the promoter holding?\">Who owns Gland Pharma, and what is the promoter holding?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/gland-pharma-share-price-target-2027-2\/#What_were_Gland_Pharmas_latest_quarterly_results\" title=\"What were Gland Pharma&#8217;s latest quarterly results?\">What were Gland Pharma&#8217;s latest quarterly results?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Gland_Pharma_Stock_Analysis_Company_Overview_and_Key_Stats\"><\/span><strong>Gland Pharma Stock Analysis: Company Overview and Key Stats<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Gland Pharma (NSE: GLAND) has a market capitalisation of Rs 54,577 crore. In FY26 it reported revenue of Rs 6,747 crore and net profit of Rs 1,027 crore. The table collects the figures the <strong>Gland Pharma share price target<\/strong> is built on.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>Company<\/td>\n<td><a href=\"https:\/\/univest.in\/stocks\/gland\/gland-pharma-ltd-share-price-today\">Gland Pharma<\/a><\/td>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>GLAND<\/td>\n<\/tr>\n<tr>\n<td>CMP (17 November 2026)<\/td>\n<td>Rs 3,385.90<\/td>\n<\/tr>\n<tr>\n<td>52-Week High<\/td>\n<td>Rs 3,429.00<\/td>\n<\/tr>\n<tr>\n<td>52-Week Low<\/td>\n<td>Rs 1,573.60<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 54,577 crore<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>44.16<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>40.55<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>5.11<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>11.57%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity<\/td>\n<td>0.02<\/td>\n<\/tr>\n<tr>\n<td>EPS (TTM)<\/td>\n<td>Rs 74.90<\/td>\n<\/tr>\n<tr>\n<td>Dividend Yield<\/td>\n<td>0.60%<\/td>\n<\/tr>\n<tr>\n<td>12-Month Base Target<\/td>\n<td>Rs 3,812<\/td>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 4,611<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk Level (not a target)<\/td>\n<td>Rs 2,646<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_Gland_Pharma_Share_Price_Target_Set_at_Rs_3812_for_2027\"><\/span><strong>Why Is Gland Pharma Share Price Target Set at Rs 3,812 for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The arithmetic is short. Trailing EPS of Rs 74.90 grown for one year gives a forward <strong>EPS estimate<\/strong> of Rs 86.32, and multiplying it by the unchanged PE of 44.16 gives the <strong>Rs 3,812<\/strong> base-case <strong>Gland Pharma stock target<\/strong>. The <strong>bull case<\/strong> adds faster earnings growth and a higher multiple, while the <strong>downside risk level<\/strong> assumes flat earnings and a lower multiple.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Earnings_Growth_Behind_the_Gland_Pharma_Target_Price_Five_Years_of_Results\"><\/span><strong>Earnings Growth Behind the Gland Pharma Target Price: Five Years of Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma grew revenue from Rs 4,625 crore in FY22 to Rs 6,747 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew more slowly, from Rs 1,212 crore to Rs 1,027 crore (-4.0% a year), which points to margin pressure alongside the sales growth.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Financial Year<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<th>EPS (Rs)<\/th>\n<th>Dividend per Share (Rs)<\/th>\n<\/tr>\n<tr>\n<td>FY22<\/td>\n<td>4,624.65<\/td>\n<td>1,211.66<\/td>\n<td>73.64<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY23<\/td>\n<td>3,865.06<\/td>\n<td>781.04<\/td>\n<td>47.43<\/td>\n<td>0.00<\/td>\n<\/tr>\n<tr>\n<td>FY24<\/td>\n<td>5,834.96<\/td>\n<td>772.46<\/td>\n<td>46.89<\/td>\n<td>20.00<\/td>\n<\/tr>\n<tr>\n<td>FY25<\/td>\n<td>5,830.11<\/td>\n<td>698.53<\/td>\n<td>42.40<\/td>\n<td>18.00<\/td>\n<\/tr>\n<tr>\n<td>FY26<\/td>\n<td>6,746.98<\/td>\n<td>1,027.32<\/td>\n<td>62.28<\/td>\n<td>20.00<\/td>\n<\/tr>\n<\/table>\n<p>FY26 revenue growth was 15.7%, faster than the four-year average of 9.9%, and net profit moved up 47.1%. EPS rose from Rs 46.89 in FY24 to Rs 62.28 in FY26. The <strong>FY27 outlook<\/strong> for the <strong>Gland Pharma price target<\/strong> depends on whether that <strong>EPS estimate<\/strong> keeps compounding.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Margins_and_the_Latest_Quarter\"><\/span><strong>Margins and the Latest Quarter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma converted 15.2% of FY26 revenue into net profit, against 12.0% in FY25, within a five-year range of 12.0% to 26.2%. EBITDA margin was 28.5% in FY26 versus 25.4% in FY25.<\/p>\n<p>In the September 2026 quarter, revenue was Rs 1,903 crore, up 21.1% from the same quarter a year earlier, while net profit of Rs 290.76 crore was up 58.3%. EBITDA came in at Rs 553.09 crore, up 38.9% year on year. The next quarterly result is the first test of whether the earnings assumption behind the <strong>Gland Pharma stock target<\/strong> holds.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Balance_Sheet_and_Cash_Flow\"><\/span><strong>Balance Sheet and Cash Flow<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Debt to equity stands at 0.02, and shareholders&#8217; equity grew from Rs 7,158 crore in FY22 to Rs 10,358 crore in FY26. Operating cash flow in FY26 was Rs 1,031 crore against capital expenditure of Rs 494.43 crore, leaving free cash flow of Rs 536.96 crore, or 1.0% of the current market capitalisation. In FY25 free cash flow was Rs 520.56 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_Check_for_the_Gland_Pharma_Stock_Target_PE_Price_to_Book_and_ROE\"><\/span><strong>Valuation Check for the Gland Pharma Stock Target: PE, Price to Book and ROE<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At a PE of 44.16 against an industry PE of 40.55, Gland Pharma trades in line with its industry. Price to book is 5.11 on a book value of Rs 647.57 per share, and return on equity is 11.57%. A PE of 44.16 equals an earnings yield of 2.3%, and the FY26 dividend of Rs 20.00 per share gives a yield of 0.60%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Shareholding_Pattern_and_Institutional_Holding\"><\/span><strong>Shareholding Pattern and Institutional Holding<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Promoters held 45.75% of Gland Pharma in September 2026, and promoter holding fell from 51.83% in September 2025 to 45.75% in September 2026. Foreign institutional investors (FII) held 10.36% and domestic institutions (DII) held 33.21%, which puts total <strong>institutional holding<\/strong> at 43.57%. FII holding rose from 7.91% in September 2025 to 10.36% in September 2026. Public shareholders own the remaining 10.67%. A meaningful institutional holding adds a layer of research coverage and trading depth.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Gland_Pharma_Share_Price_Targets_for_the_Short_Term_and_12_Months\"><\/span><strong>Gland Pharma Share Price Targets for the Short Term and 12 Months<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Gland_Pharma_Stock_Target_Levels_Technical_Setup\"><\/span><strong>Short Term Gland Pharma Stock Target Levels: Technical Setup<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 3,385.90 on 17 November 2026, Gland Pharma trades above its 50-day simple moving average of Rs 3,031.95 and above its 200-day exponential moving average of Rs 2,527.04. The 14-day RSI reads 78.6, which is overbought territory, and the MACD line sits above its signal line. The nearest <strong>resistance level<\/strong> is Rs 3,429.00 (52-week high) and the nearest support is Rs 3,031.95 (50-day simple moving average). A sustained move above Rs 3,429.00 would improve the short-term setup, while a close below Rs 3,031.95 would shift attention to the next support.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12_Month_Gland_Pharma_Target_Price_for_2027\"><\/span><strong>12 Month Gland Pharma Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>12-month target<\/strong> of <strong>Rs 3,812<\/strong> means a move of 12.6% up from Rs 3,385.90 over the next 12 months. It would also push the stock above its 52-week high of Rs 3,429.00. Anyone checking the <strong>Gland Pharma share price target<\/strong> against their own view should focus on two inputs: the EPS estimate and the <strong>PE multiple<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_EPS_Growth_and_PE_Multiple_Change_the_Gland_Pharma_Target_Price\"><\/span><strong>How EPS Growth and PE Multiple Change the Gland Pharma Target Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>EPS Growth<\/th>\n<th>PE 35.33<\/th>\n<th>PE 44.16<\/th>\n<th>PE 50.78<\/th>\n<\/tr>\n<tr>\n<td>0.0% (EPS Rs 74.90)<\/td>\n<td>Rs 2,646<\/td>\n<td>Rs 3,308<\/td>\n<td>Rs 3,803<\/td>\n<\/tr>\n<tr>\n<td>15.2% (EPS Rs 86.32)<\/td>\n<td>Rs 3,050<\/td>\n<td>Rs 3,812<\/td>\n<td>Rs 4,383<\/td>\n<\/tr>\n<tr>\n<td>21.2% (EPS Rs 90.81)<\/td>\n<td>Rs 3,208<\/td>\n<td>Rs 4,010<\/td>\n<td>Rs 4,611<\/td>\n<\/tr>\n<\/table>\n<p>Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the <strong>Gland Pharma price forecast<\/strong>, and reading down a column shows what earnings growth is worth at a fixed multiple.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Downside_Risk_for_Gland_Pharma_Stock_Target_in_2027\"><\/span><strong>Bull Case and Downside Risk for Gland Pharma Stock Target in 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Rs_4611\"><\/span><strong>Bull Case Rs 4,611<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case<\/strong> <strong>Gland Pharma price target<\/strong> needs EPS growth of 21.2%, which lifts forward EPS to Rs 90.81, and a <strong>PE multiple<\/strong> that rises 15% to 50.78. That gives <strong>Rs 4,611<\/strong>, 36.2% above the current price and above the 52-week high of Rs 3,429.00, so the stock would have to set a fresh 52-week high.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Downside_Risk_Level_Rs_2646\"><\/span><strong>Downside Risk Level Rs 2,646<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The downside risk level is not a target. It assumes EPS stays flat at Rs 74.90 and the PE falls 20% to 35.33. That gives <strong>Rs 2,646<\/strong>, 21.9% below the current price and above the 52-week low of Rs 1,573.60.<\/p>\n<table style=\"border-collapse:collapse;width:100%;\" border=\"1\" cellpadding=\"8\">\n<tr>\n<th>Scenario<\/th>\n<th>EPS Growth<\/th>\n<th>PE Multiple<\/th>\n<th>Price (Rs)<\/th>\n<th>Change vs CMP<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>21.2%<\/td>\n<td>50.78<\/td>\n<td>Rs 4,611<\/td>\n<td>+36.2%<\/td>\n<\/tr>\n<tr>\n<td>Base Case<\/td>\n<td>15.2%<\/td>\n<td>44.16<\/td>\n<td>Rs 3,812<\/td>\n<td>+12.6%<\/td>\n<\/tr>\n<tr>\n<td>Downside Risk<\/td>\n<td>0.0%<\/td>\n<td>35.33<\/td>\n<td>Rs 2,646<\/td>\n<td>-21.9%<\/td>\n<\/tr>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_the_Gland_Pharma_Target_Price_for_2027\"><\/span><strong>Key Risks to the Gland Pharma Target Price for 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Growth_Slowdown_Risk_for_the_Gland_Pharma_Price_Target\"><\/span><strong>Growth Slowdown Risk for the Gland Pharma Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Revenue in the September 2026 quarter was up 21.1% year on year, and FY26 revenue growth was 15.7%. If growth slows from here, the EPS estimate behind the Gland Pharma stock target will need revising.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_and_Size_Risk\"><\/span><strong>Liquidity and Size Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Gland Pharma has a market capitalisation of Rs 54,577 crore. <strong>Institutional holding<\/strong> is 43.57%, and promoters hold 45.75%. A company of this size trades with deep liquidity, so entry and exit are rarely a problem, and the larger risk is paying too much for slow earnings growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Valuation_and_Margin_Risk\"><\/span><strong>Valuation and Margin Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Net margin was 15.2% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 44.16 versus an industry PE of 40.55, a de-rating toward the downside-risk PE of 35.33 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Market_and_Technical_Risk\"><\/span><strong>Market and Technical Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Technical indicators add short-term risk: the 14-day RSI is 78.6 and the MACD sits above its signal line. A broad fall in the <a href=\"https:\/\/univest.in\/indices\/nifty-50\/nifty-50-share-price-today\">Nifty 50<\/a> or the <a href=\"https:\/\/univest.in\/indices\/sensex\/sensex-share-price-today\">Sensex<\/a> can override company fundamentals for weeks at a time.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Gland_Pharma\"><\/span><strong>How to Invest in Gland Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Start with the live price and volume. Any <strong>Gland Pharma share price target<\/strong> is only as current as the data behind it, and the data here is as of 17 November 2026, so refresh the Rs 3,385.90 price before acting on any level.<\/p>\n<p>Next, review the fundamentals yourself. The Univest Screener lets you check Gland Pharma&#8217;s PE, ROE, debt and shareholding in one place.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Check Gland Pharma fundamentals on the Univest Screener<\/strong><\/a><\/p>\n<p>Then compare the three <strong>Gland Pharma target price<\/strong> scenarios with your own view. If you expect EPS growth below 15.2%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.<\/p>\n<p>Decide your position size and exit levels before you buy. The support and <strong>resistance level<\/strong>s above can serve as reference points, but they are not recommendations.<\/p>\n<p>Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Gland Pharma live price and get daily stock recommendations.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The <strong>Gland Pharma share price target<\/strong> for 2027 is Rs 3,812 in the base case, with <strong>Rs 4,611<\/strong> as the bull case. The support for that view is arithmetic you can check: EPS grew 15.2% a year over FY24 to FY26, and the stock trades at a PE of 44.16. The risks are equally concrete, including a valuation that can de-rate if growth disappoints and a downside scenario that cuts the price 22% if earnings stall. Use these numbers as a framework for judging the <strong>Gland Pharma price target<\/strong>, check them against the latest filings, and size any position to your own risk appetite.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Gland_Pharma_Share_Price_Target_2027\"><\/span><strong>FAQs on Gland Pharma Share Price Target 2027<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Gland_Pharma_share_price_target_for_2027\"><\/span><strong>What is the Gland Pharma share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The base-case Gland Pharma share price target for 2027 is Rs 3,812, which is 12.6% above the price of Rs 3,385.90 on 17 November 2026. The bull case is Rs 4,611 and the downside risk level, which is not a target, is Rs 2,646. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Gland_Pharma_share_price_today\"><\/span><strong>What is the Gland Pharma share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> As of 17 November 2026, before market open, Gland Pharma (NSE: GLAND) is quoted at Rs 3,385.90, which is its last closing price from the previous session. That is 1.3% below the 52-week high of Rs 3,429.00 and 115.2% above the 52-week low of Rs 1,573.60. The market capitalisation of Rs 54,577 crore places it among large-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Gland_Pharma_a_buy_or_sell_at_the_current_price\"><\/span><strong>Is Gland Pharma a buy or sell at the current price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The data points both ways. On the positive side, EPS has grown 15.2% a year over FY24 to FY26 and the base case implies 12.6% upside; on the cautious side, the stock sits 1.3% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 2,646 is 22% below the current price. Whether Gland Pharma fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_bull_case_target_and_downside_risk_level_for_Gland_Pharma_shares\"><\/span><strong>What are the bull case target and downside risk level for Gland Pharma shares?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The bull case in the Gland Pharma share price target for 2027 is Rs 4,611, which assumes 21.2% EPS growth and a PE of 50.78, a 15% re-rating from today&#8217;s multiple. That is 36.2% above the current price and above the 52-week high of Rs 3,429.00, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 2,646, which assumes flat EPS and a PE of 35.33, 20% lower than today. It sits 21.9% below the current price and above the 52-week low of Rs 1,573.60, and it marks a risk to watch, not a target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_to_the_Gland_Pharma_price_target\"><\/span><strong>What are the main risks to the Gland Pharma price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Four risks matter most for the Gland Pharma share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. The market capitalisation of Rs 54,577 crore means liquidity is deep, so the bigger risk is paying a full price for slow earnings growth. A fall to the downside-risk PE of 35.33 would cut the price even if earnings hold.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_PE_ratio_of_Gland_Pharma_and_how_does_it_compare_with_the_industry\"><\/span><strong>What is the PE ratio of Gland Pharma and how does it compare with the industry?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The PE ratio of Gland Pharma is 44.16, against an industry PE of 40.55, which is a level close to the industry. Price to book is 5.11 and return on equity is 11.57%, and the PE equals an earnings yield of 2.3%. The base case holds the PE unchanged, so the Gland Pharma share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Who_owns_Gland_Pharma_and_what_is_the_promoter_holding\"><\/span><strong>Who owns Gland Pharma, and what is the promoter holding?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Promoters held 45.75% of Gland Pharma in September 2026. FII held 10.36%, DII held 33.21% and the public held 10.67%. Together the two institutional groups hold 43.57%. Shareholding is filed every quarter, so it is worth rechecking after each result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Gland_Pharmas_latest_quarterly_results\"><\/span><strong>What were Gland Pharma&#8217;s latest quarterly results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> In the September 2026 quarter, Gland Pharma reported revenue of Rs 1,903 crore (up 21.1% year on year) and net profit of Rs 290.76 crore (up 58.3%). For comparison, FY26 full-year revenue growth was 15.7% and net profit moved up 47.1%. Each new quarter either supports or weakens the EPS growth of 15.2% assumed in the base case.<\/p>\n<p><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Gland Pharma share price target for 2027?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The base-case Gland Pharma share price target for 2027 is Rs 3,812, which is 12.6% above the price of Rs 3,385.90 on 17 November 2026. The bull case is Rs 4,611 and the downside risk level, which is not a target, is Rs 2,646. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.\"}},{\"@type\":\"Question\",\"name\":\"What is the Gland Pharma share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"As of 17 November 2026, before market open, Gland Pharma (NSE: GLAND) is quoted at Rs 3,385.90, which is its last closing price from the previous session. That is 1.3% below the 52-week high of Rs 3,429.00 and 115.2% above the 52-week low of Rs 1,573.60. The market capitalisation of Rs 54,577 crore places it among large-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.\"}},{\"@type\":\"Question\",\"name\":\"Is Gland Pharma a buy or sell at the current price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The data points both ways. On the positive side, EPS has grown 15.2% a year over FY24 to FY26 and the base case implies 12.6% upside; on the cautious side, the stock sits 1.3% below its 52-week high and can de-rate if growth disappoints, and the downside risk level of Rs 2,646 is 22% below the current price. Whether Gland Pharma fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.\"}},{\"@type\":\"Question\",\"name\":\"What are the bull case target and downside risk level for Gland Pharma shares?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The bull case in the Gland Pharma share price target for 2027 is Rs 4,611, which assumes 21.2% EPS growth and a PE of 50.78, a 15% re-rating from today's multiple. That is 36.2% above the current price and above the 52-week high of Rs 3,429.00, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 2,646, which assumes flat EPS and a PE of 35.33, 20% lower than today. It sits 21.9% below the current price and above the 52-week low of Rs 1,573.60, and it marks a risk to watch, not a target.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks to the Gland Pharma price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Four risks matter most for the Gland Pharma share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. The market capitalisation of Rs 54,577 crore means liquidity is deep, so the bigger risk is paying a full price for slow earnings growth. A fall to the downside-risk PE of 35.33 would cut the price even if earnings hold.\"}},{\"@type\":\"Question\",\"name\":\"What is the PE ratio of Gland Pharma and how does it compare with the industry?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The PE ratio of Gland Pharma is 44.16, against an industry PE of 40.55, which is a level close to the industry. Price to book is 5.11 and return on equity is 11.57%, and the PE equals an earnings yield of 2.3%. The base case holds the PE unchanged, so the Gland Pharma share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.\"}},{\"@type\":\"Question\",\"name\":\"Who owns Gland Pharma, and what is the promoter holding?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Promoters held 45.75% of Gland Pharma in September 2026. FII held 10.36%, DII held 33.21% and the public held 10.67%. Together the two institutional groups hold 43.57%. Shareholding is filed every quarter, so it is worth rechecking after each result.\"}},{\"@type\":\"Question\",\"name\":\"What were Gland Pharma's latest quarterly results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"In the September 2026 quarter, Gland Pharma reported revenue of Rs 1,903 crore (up 21.1% year on year) and net profit of Rs 290.76 crore (up 58.3%). For comparison, FY26 full-year revenue growth was 15.7% and net profit moved up 47.1%. Each new quarter either supports or weakens the EPS growth of 15.2% assumed in the base case.\"}}]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gland Pharma share price target 2027: base Rs 3,812, bull Rs 4,611, downside risk level Rs 2,646, built from reported earnings, valuation and shareholding data.<\/p>\n","protected":false},"author":38,"featured_media":349151,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[24],"tags":[1019],"class_list":["post-349154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["349151"],"rank_math_title":["Gland Pharma Share Price Target 2027: Rs 3,812 Base"],"rank_math_description":["The Gland Pharma share price target for 2027 is Rs 3,812 against a price of Rs 3,385.90. Bull case, downside risk, earnings trend and risks explained. November 2026."],"rank_math_focus_keyword":["Gland Pharma share price target | Density Target: 1.2 to 1.5%"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/gland-pharma-share-price-target-2027-rs-3-812-base-rs-4-611-bull-and-the-risks.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/349154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=349154"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/349154\/revisions"}],"predecessor-version":[{"id":359084,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/349154\/revisions\/359084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/349151"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=349154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=349154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=349154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}